TICKERNERD
Menu
ELTXELTXHealthcare · Biotechnology

ELTX Stock Forecast: Elicio Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.94
+16.17% on the day

The 4 Wall Street analysts covering Elicio Therapeutics, Inc. hold a median 12-month price target of $10 — +415.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$42.5M
Ticker Nerd rank
36/ 100
Median analyst target
$10
Analysts covering
4
Revenue$0.0
Operating income−$10.4M
Net income−$8.2M
Free cash flow−$8.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.0%
1M
+3.7%
YTD
−75.6%
1Y
−80.3%
From 52W high
−86.9%
From 52W low
+25.2%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elicio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Size
81
Issuance
51
Volatility
45
Accruals
42
Value
38
Revisions
37
Momentum
24
Quality
17

Growth (82): Sales and profits are climbing, and climbing faster than before.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26ELTXHigh $23Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $8Median $10High $23

The green dot is the last close — the median target sits +415.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026B. Riley SecuritiesMaintainsBuy$27 → $8.00
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
18 Aug 2026HC Wainwright & Co.ReiteratesBuy—
18 June 2026Ladenburg ThalmannAssumesBuy$12
16 June 2026Jones TradingDowngradeHold—
16 June 2026Jones TradingDowngradeHold—
15 June 2026HC Wainwright & Co.MaintainsBuy$17 → $23
15 June 2026HC Wainwright & Co.MaintainsBuy—
10 June 2026B. Riley SecuritiesInitiatesBuy—
28 May 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026Ladenburg ThalmannInitiatesBuy—
13 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026Rodman & RenshawInitiatesBuy—
17 July 2025HC Wainwright & Co.MaintainsBuy—
2 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024Jones TradingInitiatesBuy—
23 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 June 2024HC Wainwright & Co.ReiteratesBuy—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
1 May 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ELTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ELTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Elicio Therapeutics, Inc. returned −80.3% against +15.6% for the S&P 500, dividends included.

ELTX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ELTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Elicio Therapeutics, Inc. (ELTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.8×

Cheaper than 65% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 22% of US stocks

EV / EBITDA
−0.8×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−774.6%

Higher than 2% of US stocks

Return on assets
−77.9%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elicio Therapeutics, Inc. (ELTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elicio Therapeutics, Inc. has a market value of $42.5M and an enterprise value of $31.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$37.7M.

  • Shares outstanding: 21.9M.

  • Trailing P/E: 5.8×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Elicio Therapeutics, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

ELTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELTXElicio Therapeutics, Inc.$42.5M36
ATNMActinium Pharmaceuticals, Inc.$43.3M76
ACETAdicet Bio, Inc.$43.0M37
SERSerina Therapeutics, Inc.$45.0M19
INMBINmune Bio, Inc.$42.8M49
KLRSKalaris Therapeutics, Inc.$42.3M23
ANVSAnnovis Bio, Inc.$42.3M28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elicio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELTX news & analysis

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

GlobeNewsWire · 24 Sept 2026positive

Elicio Therapeutics announced that new pre-specified analyses from its randomized Phase 2 AMPLIFY-7P study of ELI-002 7P (camupepimut) in resected pancreatic ductal adenocarcinoma were selected for a late-breaking Proffered Paper oral presentation at the ESMO Congress 2026 in Madrid (October 23–27, 2026). The company said the findings are expected to inform a refined Phase 3 development strategy.

Why it matters — An ELTX watcher would care because presentation of these Phase 2 analyses at a major oncology congress highlights the clinical potential of ELI-002 7P and signals progress toward the company's Phase 3 development efforts.

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 31 Aug 2026neutral

Elicio Therapeutics announced that CEO Robert Connelly and Chief Scientific Officer Pete DeMuth, PhD, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York, New York.

Why it matters — An ELTX watcher would care because the company's leadership will present at a major investment conference, providing an opportunity to hear about the clinical-stage biotech's immunotherapy programs.

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 24 Aug 2026neutral

Elicio Therapeutics announced that management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Boston, MA. Elicio is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers.

Why it matters — The conference participation gives Elicio management an opportunity to discuss the company's immunotherapy pipeline with investors and industry participants.

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 13 Aug 2026positive

Elicio Therapeutics reported second quarter 2026 financial results and disclosed plans to initiate a Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor, with or without an anti-PD-1 inhibitor, in metastatic pancreatic cancer, anticipated to begin in the fourth quarter of 2026.

Why it matters — This update signals a potential expansion of Elicio's clinical pipeline into a new combination approach for pancreatic cancer, which could broaden the therapeutic applications of its lead candidate ELI-002 7P.

FAQ

Frequently asked questions about ELTX stock

What is the ELTX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Elicio Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELTX stock a buy right now?

Of the 4 analysts covering Elicio Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elicio Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELTX?

As at 21 Oct 2026, Elicio Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will ELTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +415.5% from the last close, and Ticker Nerd's factor model ranks Elicio Therapeutics, Inc. 36 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELTX stock forecast for 2030?

No analyst covering Elicio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $23 over the next 12 months.

How has ELTX stock performed over the past year?

Elicio Therapeutics, Inc. returned -80.3% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elicio Therapeutics, Inc. do?

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer.

What is the latest news on ELTX?

The most recent item we track (GlobeNewsWire, 24 Sept 2026): "Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026". Elicio Therapeutics announced that new pre-specified analyses from its randomized Phase 2 AMPLIFY-7P study of ELI-002 7P (camupepimut) in resected pancreatic ductal adenocarcinoma were selected for a late-breaking Proffered Paper oral presentation at the ESMO Congress 2026 in Madrid (October 23–27, 2026). The company said the findings are expected to inform a refined Phase 3 development strategy.

Company

About Elicio Therapeutics, Inc.

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines, immunomodulators, and adjuvants to the lymph nodes to support a stronger immune response. Its programs include investigational therapies for KRAS-driven cancers, BRAF-driven cancers, and other mutation-defined tumor types, alongside broader efforts in cancer immunotherapy and selected infectious disease applications. Elicio Therapeutics Inc. works at the intersection of oncology and immune system engineering, using platform-based drug design to create both personalized and off-the-shelf candidates for clinically important targets. Headquartered in Boston, Massachusetts, Elicio Therapeutics Inc. is positioned as a specialized player in the biotechnology market with a focus on hard-to-treat cancers and precision immunotherapy approaches.

CEO Mr. Robert T. Connelly · 33 employees · United States · https://elicio.com